ofloxacin has been researched along with Pneumococcal Infections in 100 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Pneumococcal Infections: Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study assessed daily aspirate samples from an indwelling sinus catheter during high-dose, short-course levofloxacin (750 mg daily x 5 days) treatment of acute maxillary sinusitis." | 9.12 | Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. ( Ambrose, PG; Anon, JB; Jones, RN; Kahn, JB; Paglia, M; Xiang, J, 2007) |
| "The authors had for aim to evaluate the efficacy and tolerance of oral levofloxacin (500 mg once a day during ten days), as a treatment for acute bacterial sinusitis at risk for complications in adult patients." | 9.11 | [Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications]. ( Gehanno, P; Pessey, JJ; Serrano, E, 2005) |
| "Comparison of efficacy and safety of sparfloxacin vs ofloxacin for treatment of acute bacterial exacerbations of chronic bronchitis (ABECB)." | 9.08 | Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group. ( Bensch, G; Chodosh, S; DeAbate, CA; Harper, L; Henry, D; Jubran, A; Talbot, GH; Tipping, D, 1998) |
| "A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 7.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
| "This study assessed daily aspirate samples from an indwelling sinus catheter during high-dose, short-course levofloxacin (750 mg daily x 5 days) treatment of acute maxillary sinusitis." | 5.12 | Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. ( Ambrose, PG; Anon, JB; Jones, RN; Kahn, JB; Paglia, M; Xiang, J, 2007) |
| "The authors had for aim to evaluate the efficacy and tolerance of oral levofloxacin (500 mg once a day during ten days), as a treatment for acute bacterial sinusitis at risk for complications in adult patients." | 5.11 | [Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications]. ( Gehanno, P; Pessey, JJ; Serrano, E, 2005) |
| "Comparison of efficacy and safety of sparfloxacin vs ofloxacin for treatment of acute bacterial exacerbations of chronic bronchitis (ABECB)." | 5.08 | Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group. ( Bensch, G; Chodosh, S; DeAbate, CA; Harper, L; Henry, D; Jubran, A; Talbot, GH; Tipping, D, 1998) |
| "To assess the safety and efficacy of a ten-day oral course of ofloxacin (400 mg 12 hourly) as compared with erythromycin (400 mg every 6 hours) for treatment of lower respiratory tract infections, fifty-two adult outpatients with pulmonary infiltrates (pneumonia) or with a cough and purulent sputum (bronchitis) were evaluated." | 5.07 | Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin. ( Hooton, TM; Lipsky, BA; Pecoraro, RE; Peugeot, RL, 1991) |
| "Levofloxacin (levogyre form of ofloxacin) has been approved for the treatment of acute and chronic sinusitis, pneumonia, and exacerbation of bronchopulmonary diseases, urinary, digestive and biliary infections in adults." | 3.76 | [Levofloxacin in children]. ( Cohen, R; Grimprel, E, 2010) |
| "Fluoroquinolones are not indicated for use for the treatment of pneumonia in children; however, non-levofloxacin-susceptible Streptococcus pneumoniae (NLSSP) has emerged in South Africa among children receiving treatment for multidrug-resistant tuberculosis." | 3.75 | Molecular characterization of emerging non-levofloxacin-susceptible pneumococci isolated from children in South Africa. ( de Gouveia, L; du Plessis, M; Klugman, KP; von Gottberg, A; Wolter, N, 2009) |
| "A dose-decreasing immunocompetent sepsis mouse model was used to evaluate the in vivo effect of levofloxacin, moxifloxacin and gemifloxacin, using a ciprofloxacin/levofloxacin susceptible serotype 6B strain (ciprofloxacin MIC: 1 mg/l) and two resistant serotype 14 and 19F strains with gyrA and parC point mutations (ciprofloxacin MICs of 32 and 64 mg/l, respectively)." | 3.73 | In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. ( Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D, 2005) |
| "Levofloxacin resistance was associated with increased mortality, along with septic shock, prior use of corticosteroids, and development of ARDS, in adult patients with IPD." | 1.39 | Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort. ( Carlos, CC; Chung, DR; Hsueh, PR; Kang, CI; Kim, SH; Peck, KR; Perera, J; So, TM; Song, JH; Thamlikitkul, V; Van, PH; Wang, H; Yasin, RM, 2013) |
| " An in vitro infection model was used to simulate free pulmonary fluctuating concentrations expected after multiple dosing regimens of both drugs in humans or constant multiples of the minimum inhibitory concentration." | 1.37 | Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae. ( Dalla Costa, T; de Andrade, C; Tasso, L, 2011) |
| "Levofloxacin seems to be a good alternative treatment for patients with uncomplicated spontaneous ascites infections." | 1.36 | A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. ( Alişkan, H; Güçlü, M; Husamettin, E; Serin, E; Yakar, T, 2010) |
| "In a previous study, levofloxacin 750 mg eradicated 4 ciprofloxacin-resistant isolates of Streptococcus pneumoniae from an in vitro pharmacodynamic model (IVPM)." | 1.35 | Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae. ( Lister, PD, 2008) |
| "Ciprofloxacin resistance was greatest in people >64 years of age and least in those <16 years of age." | 1.34 | Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. ( Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG, 2007) |
| "A correlation was seen between both the area under the serum concentration curve and MIC (AUC/MIC) and the peak concentration/MIC (Cmax/MIC) versus area under the bactericidal killing curve (AUBKC) or Deltalog0-24 cfu/mL." | 1.33 | Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. ( Cars, O; Odenholt, I, 2006) |
| " For quinolone-susceptible strain ATCC49619, tosufloxacin showed bactericidal activity, given that both the AUC(0-24h)/MIC ratios at the dosage of 150 mg t." | 1.33 | Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration. ( Fukuda, Y; Mitsuyama, J; Takahata, M, 2006) |
| " Dosing regimens for gatifloxacin were 400 mg once daily (qd) administered to younger patients (<65 years) and gatifloxacin 200 mg qd to elderly patients (> or =65 years)." | 1.33 | Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. ( Hoban, DJ; Noreddin, AM; Zhanel, GG, 2005) |
| "Patients with chronic obstructive pulmonary disease are generally subjected to multiple regimens of antimicrobial treatment." | 1.33 | In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. ( Ercibengoa, M; González, A; Larruskain, J; Marimón, JM; Pérez-Trallero, E, 2005) |
| "The decision to treat an aortitis by corticotherapy must be made with caution even if the microbiological tests are negative." | 1.33 | [Infectious or inflammatory aortitis? One case report]. ( Benhamou, Y; Cailleux, N; Lévesque, H; Marie, I; Plissonnier, D; Pons, JL; Richard, C; Watelet, J, 2006) |
| " AUC0-t/MIC was strongly associated with bacterial kill throughout the dosing interval." | 1.32 | AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. ( Ariano, RE; Harding, GK; Iacovides, H; Sun, S; Zelenitsky, SA, 2003) |
| "Levofloxacin resistance was detected in 2 of 2,834 isolates (0." | 1.32 | Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. ( Critchley, IA; Evangelista, AT; Jones, ME; Karlowsky, JA; Noel, GJ; Sahm, DF; Thornsberry, C, 2003) |
| "Ciprofloxacin was less effective than the levofloxacin regimens against all four study isolates." | 1.32 | Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. ( Garrison, MW, 2003) |
| "Levofloxacin resistance was rarely associated with MDR phenotypes." | 1.32 | The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002. ( Blosser-Middleton, RS; Jones, ME; Karlowsky, JA; Sahm, DF; Thornsberry, C, 2003) |
| " pneumoniae, with standard dosing resulting in area under the concentration-time curve/MIC ratios and peak concentration/MIC ratios that resulted in 99." | 1.31 | Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. ( Hershberger, E; Rybak, MJ, 2000) |
| " Inter-subject pharmacokinetic and MIC variability may impact the probability of attaining optimal AUC:MIC ratios and hence favorable clinical outcome." | 1.31 | The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. ( Ambrose, PG; Grasela, DM, 2000) |
| "4 (100%), respectively, over the dosing period." | 1.31 | Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. ( Bui, KQ; Mattoes, H; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D; Zhong, M, 2001) |
| "Levofloxacin was also quite active, inhibiting 98-100% of the isolates at concentrations < or = 2 micrograms/ml." | 1.30 | Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. ( Jones, RN; Pfaller, MA, 1997) |
| "This has implications for the future treatment of pneumococcal infections in this country and emphasizes the need for new anti-pneumococcal agents." | 1.30 | Pneumococcal resistance in the UK. ( Goldsmith, CE; Moore, JE; Murphy, PG, 1997) |
| " In this study, the bactericidal characteristics and pharmacodynamic profiles of levofloxacin, ciprofloxacin, and ampicillin against four isolates of S." | 1.30 | Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. ( Lacy, MK; Lu, W; Nicolau, DP; Nightingale, CH; Quintiliani, R; Tessier, PR; Xu, X, 1999) |
| "The aim of this study was to compare the bactericidal efficacy of levofloxacin and ofloxacin against Streptococcus pneumoniae at different dosage regimens for both agents." | 1.30 | Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae. ( Bauernfeind, A, 1999) |
| " The dosing regimen of each drug that yielded serum levels in mice which mimic human therapeutic concentrations of the drugs, were designed." | 1.30 | Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. ( Bui, KQ; Nicolau, DP; Nightingale, CH; Onyeji, CO; Owens, RC; Quintiliani, R, 1999) |
| "We studied the pharmacokinetic parameters of four fluoroquinolones--ofloxacin, ciprofloxacin, temafloxacin and sparfloxacin--in a mouse model of Streptococcus pneumoniae-infected lung." | 1.28 | Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. ( Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Vallée, E, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.00) | 18.7374 |
| 1990's | 13 (13.00) | 18.2507 |
| 2000's | 74 (74.00) | 29.6817 |
| 2010's | 12 (12.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaseanu, C | 1 |
| Bergallo, C | 1 |
| Teglia, O | 1 |
| Jasovich, A | 1 |
| Oliva, ME | 1 |
| Dukart, G | 1 |
| Dartois, N | 1 |
| Cooper, CA | 1 |
| Gandjini, H | 1 |
| Mallick, R | 1 |
| Davies, TA | 4 |
| Yee, YC | 3 |
| Bush, K | 3 |
| Sahm, D | 1 |
| Evangelista, A | 2 |
| Goldschmidt, R | 3 |
| Sahm, DF | 6 |
| Evangelista, AT | 2 |
| Lister, PD | 1 |
| Wolter, N | 2 |
| du Plessis, M | 2 |
| von Gottberg, A | 2 |
| de Gouveia, L | 2 |
| Klugman, KP | 4 |
| Vila-Corcoles, A | 1 |
| Bejarano-Romero, F | 1 |
| Salsench, E | 1 |
| Ochoa-Gondar, O | 1 |
| de Diego, C | 1 |
| Gomez-Bertomeu, F | 1 |
| Raga-Luria, X | 1 |
| Cliville-Guasch, X | 1 |
| Arija, V | 1 |
| Sohma, M | 1 |
| Yokozawa, I | 1 |
| Kaneko, S | 1 |
| Satake, S | 1 |
| Yakar, T | 1 |
| Güçlü, M | 1 |
| Serin, E | 1 |
| Alişkan, H | 1 |
| Husamettin, E | 1 |
| Hsieh, YC | 1 |
| Chang, LY | 1 |
| Huang, YC | 1 |
| Lin, HC | 1 |
| Huang, LM | 1 |
| Hsueh, PR | 2 |
| Grimprel, E | 1 |
| Cohen, R | 1 |
| Naba, MR | 1 |
| Araj, GF | 1 |
| Baban, TA | 1 |
| Tabbarah, ZA | 1 |
| Awar, GN | 1 |
| Kanj, SS | 1 |
| Suzuki, K | 1 |
| Kurono, Y | 1 |
| Kobayashi, T | 1 |
| Nishimura, T | 1 |
| Baba, S | 1 |
| Harabuchi, Y | 1 |
| Fujisawa, T | 1 |
| Yamanaka, N | 1 |
| Ubukata, K | 1 |
| Ikeda, F | 1 |
| Luque, S | 1 |
| Grau, S | 1 |
| Valle, M | 1 |
| Colino, CI | 1 |
| Ferrer, A | 1 |
| Sunagawa, S | 1 |
| Fujita, J | 1 |
| Higa, F | 1 |
| Tateyama, M | 1 |
| Haranaga, S | 1 |
| Nakasone, I | 1 |
| Yamane, N | 1 |
| Uno, T | 1 |
| Patel, SN | 1 |
| McGeer, A | 1 |
| Melano, R | 1 |
| Tyrrell, GJ | 1 |
| Green, K | 1 |
| Pillai, DR | 1 |
| Low, DE | 4 |
| Tasso, L | 1 |
| de Andrade, C | 1 |
| Dalla Costa, T | 1 |
| Pallecchi, L | 1 |
| Riccobono, E | 1 |
| Montagnani, F | 1 |
| Di Maggio, T | 1 |
| Mantengoli, E | 1 |
| Pollini, S | 1 |
| Rossolini, GM | 1 |
| Iraurgui, P | 1 |
| Torres, MJ | 1 |
| Aznar, J | 1 |
| Kang, CI | 1 |
| Song, JH | 1 |
| Kim, SH | 1 |
| Chung, DR | 1 |
| Peck, KR | 1 |
| Thamlikitkul, V | 1 |
| Wang, H | 1 |
| So, TM | 1 |
| Yasin, RM | 1 |
| Carlos, CC | 1 |
| Van, PH | 1 |
| Perera, J | 1 |
| Pessey, JJ | 2 |
| Soussy, CJ | 1 |
| Critchley, IA | 2 |
| Blosser-Middleton, RS | 2 |
| Jones, ME | 4 |
| Karlowsky, JA | 4 |
| Karginova, EA | 1 |
| Thornsberry, C | 4 |
| Bello, S | 1 |
| Torres, A | 1 |
| Odagiri, S | 1 |
| Watanuki, Y | 1 |
| Takahashi, H | 1 |
| Shimada, J | 1 |
| Zelenitsky, SA | 1 |
| Ariano, RE | 1 |
| Iacovides, H | 1 |
| Sun, S | 1 |
| Harding, GK | 1 |
| Noel, GJ | 2 |
| Johnson, CN | 1 |
| Benjamin Jr, WH | 1 |
| Moser, SA | 1 |
| Hollingshead, SK | 1 |
| Zheng, X | 1 |
| Crain, MJ | 1 |
| Nahm, MH | 1 |
| Waites, KB | 1 |
| Anderson, KB | 1 |
| Tan, JS | 1 |
| File, TM | 1 |
| DiPersio, JR | 1 |
| Willey, BM | 1 |
| Garrison, MW | 2 |
| Ohsaki, Y | 1 |
| Tachibana, M | 1 |
| Nakanishi, K | 1 |
| Nakao, S | 1 |
| Saito, K | 1 |
| Toyoshima, E | 1 |
| Sato, M | 1 |
| Takahashi, T | 1 |
| Osanai, S | 1 |
| Itoh, Y | 1 |
| Kikuchi, K | 1 |
| Safdar, A | 1 |
| Schimmels, JA | 1 |
| Madaras-Kelly, KJ | 1 |
| Hua, CZ | 1 |
| Shang, SQ | 1 |
| Sun, XF | 1 |
| Li, JP | 1 |
| Chen, ZM | 1 |
| Yu, XL | 1 |
| Schito, AM | 1 |
| Schito, GC | 1 |
| Marrie, TJ | 1 |
| Pletz, MW | 2 |
| McGee, L | 2 |
| Jorgensen, J | 1 |
| Beall, B | 2 |
| Facklam, RR | 1 |
| Whitney, CG | 2 |
| Brian, SR | 1 |
| Kimbrough, RC | 1 |
| Brown, SD | 1 |
| Farrell, DJ | 1 |
| Morrissey, I | 2 |
| Bhavnani, SM | 1 |
| Hammel, JP | 1 |
| Jones, RN | 4 |
| Ambrose, PG | 3 |
| Richter, SS | 1 |
| Heilmann, KP | 1 |
| Beekmann, SE | 1 |
| Miller, NJ | 1 |
| Rice, CL | 1 |
| Doern, GV | 1 |
| Alkorta, M | 1 |
| Giménez, MJ | 2 |
| Vicente, D | 1 |
| Aguilar, L | 2 |
| Pérez-Trallero, E | 2 |
| Fuller, JD | 1 |
| Tarragó, D | 1 |
| Lara, N | 1 |
| Fenoll, A | 1 |
| Casal, J | 1 |
| Sevillano, D | 2 |
| Gehanno, P | 1 |
| Serrano, E | 1 |
| Marimón, JM | 1 |
| González, A | 1 |
| Ercibengoa, M | 1 |
| Larruskain, J | 1 |
| Noreddin, AM | 1 |
| Hoban, DJ | 3 |
| Zhanel, GG | 3 |
| Fukuda, Y | 1 |
| Takahata, M | 1 |
| Mitsuyama, J | 1 |
| Huelves, L | 1 |
| Martínez-Marín, C | 1 |
| López-Casla, MT | 1 |
| Gracia, M | 1 |
| Alou, L | 1 |
| del Carmen Ponte, M | 1 |
| Prieto, J | 1 |
| Soriano, F | 1 |
| Benhamou, Y | 1 |
| Plissonnier, D | 1 |
| Cailleux, N | 1 |
| Pons, JL | 1 |
| Richard, C | 1 |
| Watelet, J | 1 |
| Marie, I | 1 |
| Lévesque, H | 1 |
| Rivera, A | 1 |
| Rebollo, M | 1 |
| Miró, E | 1 |
| Mateo, M | 1 |
| Navarro, F | 1 |
| Gurguí, M | 1 |
| Mirelis, B | 1 |
| Coll, P | 1 |
| Schurek, KN | 2 |
| Adam, HJ | 2 |
| Odenholt, I | 1 |
| Cars, O | 1 |
| Oznur, AK | 1 |
| Ozer, S | 1 |
| Benzonana, NA | 1 |
| Nichol, KA | 1 |
| Hoban, CJ | 1 |
| Baudry, TJ | 1 |
| Laing, NM | 1 |
| Anon, JB | 1 |
| Paglia, M | 1 |
| Xiang, J | 1 |
| Kahn, JB | 1 |
| Kays, MB | 1 |
| Lisek, CR | 1 |
| Denys, GA | 1 |
| Dobay, O | 1 |
| Rozgonyi, F | 1 |
| Ghidán, A | 1 |
| Matuz, M | 1 |
| Nagy, K | 1 |
| Amyes, SG | 1 |
| Alonso, R | 1 |
| Mateo, E | 1 |
| Cisterna, R | 1 |
| LaPlante, KL | 1 |
| Rybak, MJ | 2 |
| Tsuji, B | 1 |
| Lodise, TP | 1 |
| Kaatz, GW | 1 |
| Ip, M | 1 |
| Chau, SS | 1 |
| Chi, F | 1 |
| Cheuk, ES | 1 |
| Ma, H | 1 |
| Lai, RW | 1 |
| Chan, PK | 1 |
| Shin, JH | 1 |
| Jung, HJ | 1 |
| Kim, HR | 1 |
| Jeong, J | 1 |
| Jeong, SH | 1 |
| Kim, S | 1 |
| Lee, EY | 1 |
| Lee, JN | 1 |
| Chang, CL | 1 |
| Leibovitz, E | 1 |
| McNeeley, DF | 1 |
| Dagan, R | 1 |
| Cohen, C | 1 |
| Mpembe, R | 1 |
| Quan, V | 1 |
| Whitelaw, A | 1 |
| Hoffmann, R | 1 |
| Govender, N | 1 |
| Meiring, S | 1 |
| Smith, AM | 1 |
| Schrag, S | 1 |
| Reichman, LB | 1 |
| Smith, JT | 1 |
| Giron, KP | 1 |
| Gross, ME | 1 |
| Musher, DM | 1 |
| Williams, TW | 1 |
| Tharappel, RA | 1 |
| Pfaller, MA | 2 |
| Goldsmith, CE | 1 |
| Moore, JE | 1 |
| Murphy, PG | 1 |
| DeAbate, CA | 1 |
| Henry, D | 1 |
| Bensch, G | 1 |
| Jubran, A | 1 |
| Chodosh, S | 1 |
| Harper, L | 1 |
| Tipping, D | 1 |
| Talbot, GH | 1 |
| Lontie, M | 1 |
| Liekens, K | 1 |
| Deschilder, I | 1 |
| Lacy, MK | 1 |
| Lu, W | 1 |
| Xu, X | 1 |
| Tessier, PR | 1 |
| Nicolau, DP | 3 |
| Quintiliani, R | 3 |
| Nightingale, CH | 3 |
| Thomson, KS | 2 |
| Chartrand, SA | 2 |
| Sanders, CC | 1 |
| Block, SL | 1 |
| Bauernfeind, A | 1 |
| Onyeji, CO | 1 |
| Bui, KQ | 2 |
| Owens, RC | 1 |
| Wortmann, GW | 1 |
| Bennett, SP | 1 |
| Hershberger, E | 1 |
| Trampuz, A | 1 |
| Wenk, M | 1 |
| Rajacic, Z | 1 |
| Zimmerli, W | 1 |
| Tauro, S | 1 |
| Dobie, D | 1 |
| Richardson, G | 1 |
| Hastings, M | 1 |
| Mahendra, P | 1 |
| Grasela, DM | 1 |
| Bergogne-Bérézin, E | 2 |
| Oteo, J | 1 |
| Alós, JI | 1 |
| Gómez-Garcés, JL | 1 |
| Xuan, D | 1 |
| Zhong, M | 1 |
| Mattoes, H | 1 |
| McNabb, J | 1 |
| Ho, PL | 1 |
| Tse, WS | 1 |
| Tsang, KW | 1 |
| Kwok, TK | 1 |
| Ng, TK | 1 |
| Cheng, VC | 1 |
| Chan, RM | 1 |
| Black, J | 1 |
| Moland, ES | 1 |
| Nealy, L | 1 |
| Nicodemo, AC | 1 |
| Mendes, CM | 1 |
| Oplustil, CP | 1 |
| Sinto, S | 1 |
| Rossi, C | 1 |
| Sternon, J | 1 |
| Ross, JJ | 1 |
| Worthington, MG | 1 |
| Gorbach, SL | 1 |
| Tillotson, GS | 1 |
| Zhao, X | 1 |
| Drlica, K | 1 |
| Hutchinson, J | 1 |
| White, RL | 1 |
| Enzweiler, KA | 1 |
| Friedrich, LV | 1 |
| Wagner, D | 1 |
| Hoban, D | 1 |
| Bosso, JA | 1 |
| Vallée, E | 1 |
| Azoulay-Dupuis, E | 1 |
| Pocidalo, JJ | 1 |
| Peugeot, RL | 1 |
| Lipsky, BA | 1 |
| Hooton, TM | 1 |
| Pecoraro, RE | 1 |
| Davies, BI | 1 |
| Maesen, FP | 1 |
| Teengs, JP | 1 |
| Baur, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia[NCT00079885] | Phase 3 | 430 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia[NCT00081575] | Phase 3 | 434 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| An Open-label, Multi-center, Non-comparative Sinus Puncture Study of 750 mg, Short-course Levofloxacin in the Treatment of Acute Maxillary Sinusitis[NCT00236652] | Phase 3 | 18 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ofloxacin and Pneumococcal Infections
| Article | Year |
|---|---|
[Update on levofloxacin in the management of acute sinusitis with risk of complications].
Topics: Abscess; Acute Disease; Anti-Infective Agents; Cellulitis; Clinical Trials as Topic; Disease Progres | 2002 |
[New microbiological data on the susceptibility of Pneumococci to levofloxacin].
Topics: Anti-Infective Agents; Drug Resistance, Microbial; France; Humans; Levofloxacin; Ofloxacin; Pneumoco | 2002 |
Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Humans; Italy; Levofloxacin; Micro | 2004 |
A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Female; F | 2005 |
[Third and fourth generation fluoroquinolones].
Topics: Administration, Oral; Anti-Infective Agents; Aza Compounds; Belgium; Biological Availability; Drug M | 2001 |
6 trials available for ofloxacin and Pneumococcal Infections
| Article | Year |
|---|---|
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial I | 2008 |
Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Azi | 2004 |
[Levofloxacin in the treatment of acute and bacteriologically documented sinusitis with high risk of complications].
Topics: Acute Disease; Adolescent; Adult; Africa, Southern; Aged; Bacterial Infections; Female; France; Haem | 2005 |
Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Catheters, Indwelling; Dose-Response Relationship, Drug | 2007 |
Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Chlamy | 1998 |
Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin.
Topics: Adult; Aged; Bronchitis; Chlamydia Infections; Erythromycin; Female; Humans; Legionnaires' Disease; | 1991 |
89 other studies available for ofloxacin and Pneumococcal Infections
| Article | Year |
|---|---|
Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Base Sequence; Chi-Square Distribution; DNA Gyrase; | 2008 |
Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluoroquinolone-resistant Streptococcus pneumoniae TRUST Surveillance isolates since 2001.
Topics: Clone Cells; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Microbia | 2008 |
Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; | 2008 |
Molecular characterization of emerging non-levofloxacin-susceptible pneumococci isolated from children in South Africa.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; Carrier State; C | 2009 |
Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Blood | 2009 |
[Epidemiological study of levofloxacin-resistant Streptococcus pneumoniae isolated from 2003 through 2006 in Japan].
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Epidemiologic Methods; Humans; Japan; Levofloxaci | 2009 |
A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Bacterial Infections; Cefepime | 2010 |
Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Anti-Bacterial Agents; Base Seq | 2010 |
[Levofloxacin in children].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Child; Community-Acquired Infections; Humans; Le | 2010 |
Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in Lebanon: a report of three cases.
Topics: Aged; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Clarithromycin; Drug Resistance, | 2010 |
[Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; | 2010 |
Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient.
Topics: Anti-Bacterial Agents; Body Weight; Humans; Infusions, Intravenous; Levofloxacin; Middle Aged; Obesi | 2011 |
Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cluster Analysis; DNA, Bacterial; Drug Resistance, Bacter | 2011 |
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisom | 2011 |
Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Area Under Curve; Culture Media; Fluoroquinolones; Gatifloxacin; Humans; Levo | 2011 |
Antipneumococcal activity of ulifloxacin compared to levofloxacin and ciprofloxacin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, | 2011 |
Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
Topics: Adult; Anti-Bacterial Agents; Bacterial Proteins; Biological Transport; DNA Gyrase; DNA Mutational A | 2012 |
Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Femal | 2013 |
Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000.
Topics: Anti-Infective Agents; Asia; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Electroph | 2002 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciproflo | 2003 |
[Epidemiological study on patients with pneumococcal respiratory tract infection in a Japanese health facility during the past year].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ceph | 2001 |
AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Culture Media; Dose-Response Relationship, D | 2003 |
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Azithromycin; Child; Child, Preschool; Drug Resistan | 2003 |
Genetic relatedness of levofloxacin-nonsusceptible Streptococcus pneumoniae isolates from North America.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Capsules; Bacterial Typing Techniques; Drug | 2003 |
Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Humans; Imm | 2003 |
Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Area Under Curve; Ciprofloxacin; Humans; Kinetics; Levofloxacin; Microbial Se | 2003 |
Alterations in penicillin binding protein gene of Streptococcus pneumoniae and their correlation with susceptibility patterns.
Topics: Aminoacyltransferases; Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Carrier Proteins; Cl | 2003 |
Efficacy of vancomycin plus levofloxacin combination therapy for refractory pericarditis due to multiresistant Streptococcus pneumoniae.
Topics: Adult; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Human | 2003 |
The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Global Health; Humans; Levofloxacin; Mi | 2003 |
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Topics: Analysis of Variance; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistanc | 2003 |
[Antibiotics-resistance pattern and genetic type of Streptococcus pneumoniae isolated from children in Hangzhou].
Topics: Anti-Bacterial Agents; Cefotaxime; Child, Preschool; China; Chloramphenicol; Drug Resistance, Bacter | 2004 |
Quinolone resistance among pneumococci: therapeutic and diagnostic implications.
Topics: Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Levoflox | 2004 |
Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacter | 2004 |
Salvage of a prosthetic knee joint infected with resistant pneumococcus. A case report.
Topics: Aged; Anti-Infective Agents; Arthritis, Infectious; Arthroplasty, Replacement, Knee; Azithromycin; D | 2004 |
Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Community-Acquired Infections; Drug Resistance, Bacterial | 2004 |
Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Levofloxac | 2005 |
The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; | 2005 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DN | 2005 |
Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive Streptococcus pneumoniae isolates in the United States.
Topics: Anti-Bacterial Agents; DNA Topoisomerases, Type II; Drug Resistance, Bacterial; Fluoroquinolones; Ge | 2005 |
Specific antibodies, levofloxacin, and modulation of capsule-associated virulence in Streptococcus pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Antibody Specificity; Area Under Curve; Bacte | 2005 |
In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophor | 2005 |
Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
Topics: Adult; Aged; Community-Acquired Infections; Drug Administration Schedule; Epidemiologic Methods; Flu | 2005 |
Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Gene Expression | 2006 |
Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration.
Topics: Anti-Bacterial Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Resistance, Bacteria | 2006 |
Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; DNA | 2006 |
[Infectious or inflammatory aortitis? One case report].
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Aortic Aneurysm, Abdominal; Aortic Dissection; | 2006 |
Superantigen gene profile, emm type and antibiotic resistance genes among group A streptococcal isolates from Barcelona, Spain.
Topics: Alleles; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance; Erythromycin; | 2006 |
Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial | 2006 |
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Escherichia coli; Escherichia coli | 2006 |
[Antibiotic resistance in Streptococcus pneumoniae strains isolated from sterile body sites].
Topics: Anti-Bacterial Agents; Bacteremia; Cerebrospinal Fluid; Dacryocystitis; Drug Resistance, Bacterial; | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; | 2007 |
Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology.
Topics: Anti-Bacterial Agents; Humans; In Vitro Techniques; Ketolides; Levofloxacin; Macrolides; Microbial S | 2007 |
The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; | 2006 |
Detection of parC mutations in Streptococcus pneumoniae by Real-time PCR and Taqman-MGB probes.
Topics: Anti-Infective Agents; Aspartic Acid; Codon; DNA Mutational Analysis; DNA Topoisomerase IV; Drug Res | 2007 |
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
Topics: Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemiflo | 2007 |
Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and -nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Drug Resistance, Bacterial; Fluoroquinolones; Hong Kong; | 2007 |
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Er | 2007 |
Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacin.
Topics: Acute Disease; Anti-Bacterial Agents; Child, Preschool; Drug Resistance, Bacterial; Electrophoresis, | 2008 |
Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.
Topics: Adolescent; Anti-Bacterial Agents; Antitubercular Agents; Child; Child, Preschool; Cross Infection; | 2008 |
Tuberculosis drug resistance comes full circle.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Ofloxacin; Pneumoc | 2008 |
Activity of new 4-quinolones in combination with erythromycin or tetracycline against S. pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Therapy, Combination; Erythromycin; Fluoroquinolo | 1995 |
In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Colony Count, Microbial; | 1995 |
Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; In Vitro | 1997 |
Pneumococcal resistance in the UK.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Chloramphenicol; Ciprofloxacin; Drug R | 1997 |
In vitro activity of newer quinolones on Streptococcus pneumoniae isolated from outpatients.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Cefurox | 1998 |
Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.
Topics: Ampicillin; Ampicillin Resistance; Anti-Infective Agents; Ciprofloxacin; Culture Media; Drug Resista | 1999 |
In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Child; Humans; Lactams; Levofloxacin; Microbial Sensit | 1999 |
Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pneumococcal In | 1999 |
Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
Topics: Acute Kidney Injury; Administration, Cutaneous; Animals; Anti-Infective Agents; Bacteremia; Ciproflo | 1999 |
Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Drug Resistance, Microbial; Fatal Outcome; Humans; Levofloxacin; Male; Mening | 1999 |
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Blood Coagulation; Ciprofloxacin; Fibrin; Fluoroquinolones; Gatifloxacin; Hum | 2000 |
Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.
Topics: Anti-Infective Agents; Blister; Body Fluids; Granulocytes; Humans; Levofloxacin; Microbial Sensitivi | 2000 |
Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carm | 2000 |
The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Area Under Curve; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Micro | 2000 |
[Resistance and new antibiotic strategies. The other new molecules].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Outer Membrane Proteins; Drug Resistance, Mi | 2000 |
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study.
Topics: Anti-Infective Agents; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pneumococcal In | 2001 |
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Female; Fluoroquinolones; Lev | 2001 |
Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999).
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Humans; Levofloxacin; Macr | 2000 |
Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Case-Control Studies; Drug Resistance, Microbial; Fe | 2001 |
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Child, Pre | 2001 |
Trends in ciprofloxacin nonsusceptibility and levofloxacin resistance among Streptococcus pneumoniae isolates in North America.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; North Ameri | 2001 |
In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; | 2001 |
Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
Topics: Anti-Infective Agents; Drug Resistance, Microbial; Humans; Levofloxacin; Microbial Sensitivity Tests | 2001 |
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
Topics: Aged; Anti-Infective Agents; Bacteremia; Drug Resistance, Bacterial; Fatal Outcome; Humans; Levoflox | 2002 |
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Humans; Levofloxacin; Ofloxacin; Pneumococcal Inf | 2002 |
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
Topics: Anti-Infective Agents; Canada; Drug Resistance, Bacterial; Drug Utilization; Hospitals; Humans; Levo | 2002 |
Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ceftriaxone; Ch | 2002 |
Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Lung Diseas | 1991 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |